facebook
twitter
rss
account
search
search
 

PharmAthene has success with phase I trial

Dec. 8, 2009 at 1:10 PM   |   Comments

ANNAPOLIS, Md., Dec. 8 (UPI) -- U.S. biological defense company PharmAthene Inc. announced its chemical nerve agent countermeasure has shown promising effectiveness in early trials.

Maryland-based PharmAthene announced a phase I clinical trial for its Protexia, under development to counter chemical nerve agent threats, has shown effective in initial testing in preventing toxicity.

PharmAthene is working with the Defense Department to develop a countermeasure for troops and the emergency first response community in the event of exposure to chemical nerve agents.

"These initial safety data in humans, coupled with available efficacy data in animals, suggest the potential for Protexia as a valuable medical countermeasure for nerve agent toxicity," David Wright, PharmAthene president and chief executive officer, said in a statement.

"Preclinical studies suggest that in contrast to currently available treatments, Protexia is the first medical countermeasure that can provide protection against both the physiological and neurological toxicities associated with nerve agent poisoning."

© 2009 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Recommended UPI Stories
Most Popular
1
Verizon will soon let you choose what TV channels you want to pay for Verizon will soon let you choose what TV channels you want to pay for
2
Etsy bans sale of items with Redskins name, imagery Etsy bans sale of items with Redskins name, imagery
3
Meggitt receives $17.7 million Army order for target systems Meggitt receives $17.7 million Army order for target systems
4
Organic food brand at Kroger's to hit $1B in sales Organic food brand at Kroger's to hit $1B in sales
5
Lockheed Martin opens technology center
Trending News
Video
x
Feedback